<bill session="107" type="h" number="3452" updated="2013-07-14T18:58:13-04:00">
  <state datetime="2001-12-11">REFERRED</state>
  <status>
    <introduced datetime="2001-12-11"/>
  </status>
  <introduced datetime="2001-12-11"/>
  <titles>
    <title as="introduced" type="short">Best Pharmaceuticals for Children Act</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act to improve the safety and efficacy of pharmaceuticals for children.</title>
  </titles>
  <sponsor id="400161"/>
  <cosponsors>
    <cosponsor id="400124" joined="2001-12-11"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-12-11">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2001-12-28">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="107" type="s" number="1789"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Administrative remedies"/>
    <term name="Bioethics"/>
    <term name="Cancer"/>
    <term name="Chemotherapy"/>
    <term name="Child health"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Congress"/>
    <term name="Congressional investigations"/>
    <term name="Congressional reporting requirements"/>
    <term name="Cost effectiveness"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug adulteration"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drug interactions"/>
    <term name="Drug therapy"/>
    <term name="Drug utilization"/>
    <term name="Economic impact statements"/>
    <term name="Economics and public finance"/>
    <term name="Executive reorganization"/>
    <term name="Families"/>
    <term name="Federal advisory bodies"/>
    <term name="Federal aid to medical research"/>
    <term name="Finance and financial sector"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Government publicity"/>
    <term name="Governmental investigations"/>
    <term name="Health insurance"/>
    <term name="Health insurance industry"/>
    <term name="Hospital care"/>
    <term name="Human experimentation in medicine"/>
    <term name="Infants"/>
    <term name="Informed consent (Medical law)"/>
    <term name="Insurance premiums"/>
    <term name="Intellectual property"/>
    <term name="Labeling"/>
    <term name="Law"/>
    <term name="Medicaid"/>
    <term name="Medical economics"/>
    <term name="Medical ethics"/>
    <term name="Medical research"/>
    <term name="Minorities"/>
    <term name="Minority health"/>
    <term name="Parent and child"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Pharmacists"/>
    <term name="Research grants"/>
    <term name="Science, technology, communications"/>
    <term name="Social welfare"/>
    <term name="Telephone"/>
    <term name="User charges"/>
  </subjects>
  <amendments/>
  <summary>12/11/2001--Introduced.
Best Pharmaceuticals for Children Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services, through the National Institutes of Health, to develop an annual list of approved drugs for which: (1) there is an approved or pending new drug application or no patent or market exclusivity protection; and (2) additional pediatric safety and effectiveness studies are needed. Directs the Secretary to award contracts to entities with appropriate experience for pediatric clinical trials of such drugs.Establishes a Food and Drug Administration (FDA) contract process for related labeling changes.Amends the Federal Food, Drug, and Cosmetic Act to: (1) eliminate the user fee waiver for pediatric supplements to a human drug application; (2) provide priority status for pediatric supplements; (3) include neonates within the definition of pediatric studies; (4) provide for dissemination of pediatric supplement information; and (5) set forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs.Directs the Secretary to establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities.Includes within the purposes and activities of the Foundation for the National Institutes of Health the collection of funds for pediatric pharmacological research.Directs the Secretary to contract with the Institute of Medicine to review Federal regulations, reports, and support for research involving children, with particular attention to issues of compensation, informed consent, and risk/ benefits assessments in terms of research versus therapeutic treatment.</summary>
</bill>
